Gupta Deepak, Christensen Carl, Soskin Vitaly
Middle East J Anaesthesiol. 2013 Oct;22(3):273-81.
To compare adequacy of peri-partum pain management with or without neuraxial opioids in patients on buprenorphine maintenance therapy (BMT).
After institutional review board approval for the study protocol, retrospective peripartum anesthesia/analgesia data of BMT patients for five-year period were accessed and analyzed.
Out of reviewed 51 patient charts, nineteen patients were found eligible for final comparative analysis. The daily amounts of peri-partum rescue analgesics with vs without neuraxial opioids were equianalgesic doses of parenteral hydromorphone (10.7 +/- 13.8 mg vs 2.6 +/- 0.7 mg, P = 0.45 for vaginal delivery; 16.4 +/- 21.1 mg vs 5.3 +/- 3.6 mg, P = 0.42 for elective cesarean section (CS)), oral ibuprofen (1.1 +/- 0.5g vs 0.8 +/- 0.4g, P = 0.37 for vaginal delivery; 1.1 +/- 0.2g vs 1.6 +/- 0.6g, P = 0.29 for elective CS), and acetaminophen (0.2 +/- 0.4g vs 0 +/- 0g, P = 0.56 for vaginal delivery; 0.3 +/- 0.3g vs 0.2 +/- 0.2g, P = 0.81 for elective CS). In the patients who underwent emergent CS after failed labor (all had received epidural opioids), there was clinical trend for higher daily amounts ofperi-partum rescue analgesics (parenteral hydromorphone 35.6 +/- 37.5 mg; oral ibuprofen 1.2 +/- 0.4g; oral acetaminophen 1.2 +/- 0.5g), when compared with vaginal delivery patients or elective CS patients who all had received neuraxial opioids.
As the study was underpowered (n = 19), future adequately powered studies are required to conclude for-or-against the use ofneuraxial opioids in BMT patients; and pro-nociceptive activation by neuraxial opioids may be worth investigating to improve our understanding of peripartum pain management of BMT patients.
比较接受丁丙诺啡维持治疗(BMT)的患者在围产期使用或不使用神经轴索阿片类药物时疼痛管理的充分性。
在机构审查委员会批准研究方案后,获取并分析了BMT患者五年期间的围产期麻醉/镇痛回顾性数据。
在审查的51份患者病历中,有19名患者符合最终比较分析的条件。使用与未使用神经轴索阿片类药物的患者围产期急救镇痛药的每日用量分别为等效镇痛剂量的胃肠外氢吗啡酮(阴道分娩时为10.7±13.8毫克对2.6±0.7毫克,P = 0.45;择期剖宫产时为16.4±21.1毫克对5.3±3.6毫克,P = 0.42)、口服布洛芬(阴道分娩时为1.1±0.5克对0.8±0.4克,P = 0.37;择期剖宫产时为1.1±0.2克对1.6±0.6克,P = 0.29)和对乙酰氨基酚(阴道分娩时为0.2±0.4克对0±0克,P = 0.56;择期剖宫产时为0.3±0.3克对0.2±0.2克,P = 0.81)。在分娩失败后接受急诊剖宫产的患者(均接受了硬膜外阿片类药物)中,与均接受了神经轴索阿片类药物的阴道分娩患者或择期剖宫产患者相比,围产期急救镇痛药的每日用量有增加的临床趋势(胃肠外氢吗啡酮35.6±37.5毫克;口服布洛芬1.2±0.4克;口服对乙酰氨基酚1.2±0.5克)。
由于本研究样本量不足(n = 19),未来需要进行有足够样本量的研究,以确定是否支持在BMT患者中使用神经轴索阿片类药物;神经轴索阿片类药物的促痛觉激活作用可能值得研究,以增进我们对BMT患者围产期疼痛管理的理解。